Konstantinos Xynos
Vermögen: 2 Mio $ am 31.05.2026
Vermögen: 2 Mio $ am 31.05.2026
Konstantinos Xynos currently works at Replimune Group, Inc., as Chief Medical Officer from 2022.
Dr. Xynos also formerly worked at Deciphera Pharmaceuticals, Inc., as Vice President & Head-Global Medical Affairs from 2019 to 2021.
Dr. Xynos received his undergraduate degree in 1991 from the University of Illinois, Masters Business Admin degree in 2013 from the University of Strathclyde, doctorate degree in 1997 from Aristotle University of Thessaloniki, and doctorate degree in 2012 from National & Kapodistrian University of Athens.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 18.05.2026 | 235.662 ( 0,3 % ) | 2 Mio $ | 31.05.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| REPLIMUNE GROUP, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.12.2022 |
| Unternehmen | Position | Ende |
|---|---|---|
| DECIPHERA PHARMACEUTICALS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2021 |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 6 |
|---|---|
University of Illinois
University of Illinois Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Strathclyde
University of Strathclyde Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Aristotle University of Thessaloniki
Aristotle University of Thessaloniki Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
National & Kapodistrian University of Athens
National & Kapodistrian University of Athens Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Replimune Group, Inc.
Replimune Group, Inc. BiotechnologyHealth Technology Develops oncolytic immunotherapies | Health Technology |
Deciphera Pharmaceuticals, Inc.
Deciphera Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops novel drug candidates to improve the lives of cancer patients | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen